(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
31 May 2012 (31.05.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/071372 A2

(51) International Patent Classification:
A61K 39/00 (2006.01)

(21) International Application Number:
PCT/US2011/061766

(22) International Filing Date:
22 November 2011 (22.11.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/416,409	23 November 2010 (23.11.2010)	US
61/481,958	3 May 2011 (03.05.2011)	US
61/551,032	25 October 2011 (25.10.2011)	US

(71) Applicant *(for all designated States except US)*: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **OKAMOTO, Haruka** [JP/US]; 837 Washington Ave. #8L, Bronx, NY 10451 (US). **SLEEMAN, Mark** [US/AU]; 9/168 Toorak Road West, South Tarra 3141, Melbourne Victoria (AU). **HARP, Joyce** [US/US]; 1 Renaissance Square #14A, White Plains, NY 10601 (US).

(74) Agent: **MALLON, Veronica**; Regeneron Pharmaceuticals, INC., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2012/071372 A2

(54) Title: HUMAN ANTIBODIES TO THE GLUCAGON RECEPTOR

(57) Abstract: The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.